Overview

A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis

Status:
Not yet recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

The study is designed to investigate efficacy and safety of KBL697 in patients with mild to moderate active ulcerative colitis. KBL697 has been developed as a potential new treatment for ulcerative colitis.

Phase:

Phase 2

Details

Lead Sponsor:

KoBioLabs

Treatments:

Vancomycin